Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Adamo, Vincenzo [1 ]
Festa, Vincenzo [1 ]
Restuccia, Eleonora [1 ]
Chiofalo, Giuseppe [1 ]
Maisano, Carmelo [1 ]
Picciotto, Maria [1 ]
Alafaci, Elisabetta [1 ]
Tortora, Giampaolo [2 ]
机构：
[1] AO Univ Polyclin G Martino, Dept Human Pathol, Med Oncol & Integrated Therapies Unit, Messina, Italy
[2] Univ Naples Federico 2, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [21] Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)
    Bullock, K. E.
    Hurwitz, H. I.
    Uronis, H. E.
    Morse, M. A.
    Blobe, G. C.
    Hsu, S. D.
    Zafar, S. Y.
    Nixon, A. B.
    Howard, L. A.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Quality of life (QoL) with capecitabine in patients with metastatic colorectal cancer (MCRC)
    Beato, C. A. M.
    Van Eyll, B.
    Federico, M. H.
    Perdicaris, M. R.
    Skare, N.
    Cabral, S.
    Saltz, E.
    Franke, F.
    Moura, G. L.
    Paula, F. U.
    EJC SUPPLEMENTS, 2005, 3 (02): : 365 - 365
  • [23] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
    Kozloff, M.
    Cohn, A.
    Christiansen, N.
    Flynn, P.
    Kabbinavar, F.
    Robles, R.
    Ulcickas-Yood, M.
    Sarkar, S.
    Hambleton, J.
    Grothey, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [24] Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
    Petrioli, Roberto
    Francini, Edoardo
    Cherri, Sara
    Torre, Pamela
    Fiaschi, Anna Ida
    Miano, Salvatora Tindara
    Marrelli, Daniele
    Rovello, Franco
    Francini, Guido
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E663 - E669
  • [25] PRELIMINARY EFFICACY, SAFETY AND OPERABILITY OF BEVACIZUMAB(BV) PLUS CAPECITABINE PLUS OXALIPLATIN (XELOX) AS FIRST-LINE THERAPY IN JAPANESE PATIENTS (PTS) WITH INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Yamaguchi, K.
    Boku, N.
    Kato, K.
    Komatsu, Y.
    Muro, K.
    Hamamoto, Y.
    Sato, A.
    Koizumi, W.
    Mizunuma, N.
    Takiuchi, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [26] CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) plus bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial
    Ziras, N.
    Polyzos, A.
    Kakolyris, S.
    Xenidis, N.
    Kentepozidis, N.
    Athanasiadis, A.
    Stergiou, I.
    Androulakis, N.
    Vamvakas, L.
    Souglakos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice
    Rossi, Luigi
    Veltri, Enzo
    Zullo, Angelo
    Zoratto, Federica
    Colonna, Maria
    Di Seri, Marisa
    Longo, Flavia
    Mottolese, Marcella
    Giannarelli, Diana
    Ruco, Luigi
    Romiti, Adriana
    Barucca, Viola
    Adua, Daniela
    Tomao, Silverio
    FUTURE ONCOLOGY, 2012, 8 (09) : 1193 - 1197
  • [28] Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab
    Al-Shamsi, Humaid O.
    Anjum, Mahraz
    Al Farsi, Abdulaziz
    Shen, Hua
    Linkins, Lori-Ann
    Cook, Richard J.
    Major, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] Predictive serum biomarkers in metastatic colorectal cancer (mCRC) patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (BVZ) (GEMCAD 09-01).
    Pineda, Estela
    Salud, Antonieta
    Vila-Navarro, Elena
    Jose Safont, Maria
    Garcia-Giron, Carlos
    Aparicio, Jorge
    Vera, Ruth
    Pilar Escudero, M.
    Casado, Enrique
    Bosch, Carlos
    Bohn, Uriel
    Perez Carrion, Ramon Maria
    Carmona Bayonas, Alberto
    Ramon Ayuso, Juan
    Ripolles, Tomas
    Bouzas, Rosa
    Gironella, Meritxell
    Garcia-Albeniz, Xabier
    Feliu, Jaime
    Maurel, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress
    Wainberg, Z.
    Wang, L.
    Yue, H.
    Motwani, M.
    Kasichayanula, S.
    Blaney, M.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2018, 29
12345